NDAORALTABLET
Approved
Dec 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORETICYL 25 is a fixed-dose oral antihypertensive tablet combining deserpidine (an alkaloid antihypertensive) and hydrochlorothiazide (a thiazide diuretic). It was approved in 1959 for the treatment of hypertension. The combination leverages two synergistic mechanisms to reduce blood pressure in patients with moderate hypertension.
LOE Approaching
As a legacy product approaching loss of exclusivity with minimal linked job openings, this brand likely operates as a cash-generating asset with a lean, maintenance-focused team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ORETICYL 25 offers negligible career advancement opportunities; no active job postings are linked to this product. Working on this brand would involve legacy product stewardship and maintenance rather than market growth, innovation, or professional development.
Brand Manager (legacy)Regulatory Affairs Specialist
Worked on ORETICYL 25 at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.